ORK Stock Analysis: Orkla ASA | OL
Packaged Foods | OL, Norway | Market Cap: 87.085m NOK | 12M Return: -6.9% | NO0003733800 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 142M
EPS Trend: 98.0%
Qual. Beats: 0
Rev. Trend: 92.9%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Orkla ASA is a Norwegian industrial investment company that owns and develops branded consumer-oriented businesses across food, coatings, personal care, and household products. Its portfolio spans decorative paints and marine coatings, frozen pizza, condiments, ready-to-eat meals, snacks, confectionery, and bakery and plant-based foods, alongside branded consumer health products (including wound care and oral health under names such as Möllers, Jordan, and Salvequick), spices, cleaning and hygiene items, painting accessories, and health and sports nutrition. It also runs a franchised pizza business. The company is headquartered in Oslo, was founded in 1654, and trades on the Oslo Stock Exchange under the ticker ORK.
Operating as a multi-brand industrial investment company rather than a single-product manufacturer, Orkla manages a diversified portfolio of largely consumer staples brands, which is reflected in its classification under GICS Packaged Foods & Meats within the broader Consumer Staples sector. This structure allows Orkla to allocate capital across unrelated categories such as coatings, food, and personal care, sharing centralized brand-building and supply-chain capabilities across distinct operating subsidiaries.
- Jotun divestment proceeds fund branded consumer health M&A
- Branded foods margins squeezed by cocoa and dairy inflation
- Nordic private label competition pressures packaged foods volume
| Net Income: 6.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.44 > 1.0 |
| NWC/Revenue: 3.62% < 20% (prev 5.50%; Δ -1.88% < -1%) |
| CFO/TA 0.17 > 3% & CFO 15.0b > Net Income 6.82b |
| Net Debt (876.0m) to EBITDA (9.69b): 0.09 < 3 |
| Current Ratio: 1.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (968.6m) vs 12m ago -3.09% < -2% |
| Gross Margin: 48.54% > 18% (prev 50.56%; Δ -2.02% > 0.5%) |
| Asset Turnover: 80.70% > 50% (prev 80.82%; Δ -0.13% > 0%) |
| Interest Coverage Ratio: 9.10 > 6 (EBIT TTM 6.97b / Interest Expense TTM 766.0m) |
| A: 0.03 (Total Current Assets 23.2b - Total Current Liabilities 20.7b) / Total Assets 87.5b |
| B: 0.46 (Retained Earnings 40.4b / Total Assets 87.5b) |
| C: 0.08 (EBIT TTM 6.97b / Avg Total Assets 87.8b) |
| D: 1.02 (Book Value of Equity 42.3b / Total Liabilities 41.7b) |
| Altman-Z'' = 3.30 = A |
| DSRI: 1.02 (Receivables 9.27b/9.11b, Revenue 70.8b/71.1b) |
| GMI: 1.04 (GM 50.56% / 48.54%) |
| AQI: 0.98 (AQ_t 0.52 / AQ_t-1 0.53) |
| SGI: 1.00 (Revenue 70.8b / 71.1b) |
| TATA: -0.09 (NI 6.82b - CFO 15.0b) / TA 87.5b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at NOK 93.35 with a total of 1,587,254 shares traded. Over the past week, the price has changed by +3.09%, over one month by -2.81%, over three months by -11.52% and over the past year by -6.86%.
Current recommended Stop Loss: 91.40 (which is 2.1% or 1.3 ATR below the current price).
Orkla ASA has no consensus analysts rating.
P/E Trailing = 13.7823
P/E Forward = 13.369
P/S = 1.2296
P/B = 2.0567
P/EG = 1.138
Revenue TTM = 70.8b NOK
EBIT TTM = 6.97b NOK
EBITDA TTM = 9.69b NOK
Long Term Debt = 13.9b NOK (from longTermDebt, last quarter)
Short Term Debt = 6.47b NOK (from shortLongTermDebt, last quarter)
Debt = 2.32b NOK (Leases only: 2.32b)
Net Debt = 876.0m NOK (calculated: Debt 2.32b - CCE 1.45b)
Enterprise Value = 88.0b NOK (87.1b + Debt 2.32b - CCE 1.45b)
Interest Coverage Ratio = 9.10 (Ebit TTM 6.97b / Interest Expense TTM 766.0m)
EV/FCF = 13.07x (Enterprise Value 88.0b / FCF TTM 6.73b)
FCF Yield = 7.65% (FCF TTM 6.73b / Enterprise Value 88.0b)
FCF Margin = 9.50% (FCF TTM 6.73b / Revenue TTM 70.8b)
Net Margin = 9.62% (Net Income TTM 6.82b / Revenue TTM 70.8b)
Gross Margin = 48.54% ((Revenue TTM 70.8b - Cost of Revenue TTM 36.4b) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.01 (Enterprise Value 88.0b / Total Assets 87.5b)
Interest Expense / Debt = 32.97% (Interest Expense 766.0m / Debt 2.32b)
Taxrate = 16.33% (1.38b / 8.42b)
NOPAT = 5.84b (EBIT 6.97b * (1 - 16.33%))
Current Ratio = 1.12 (Total Current Assets 23.2b / Total Current Liabilities 20.7b)
Debt / Equity = 0.05 (Debt 2.32b / totalStockholderEquity, last quarter 42.3b)
Debt / EBITDA = 0.09 (Net Debt 876.0m / EBITDA 9.69b)
Debt / FCF = 0.13 (Net Debt 876.0m / FCF TTM 6.73b)
Total Stockholder Equity = 46.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.77% (Net Income 6.82b / Total Assets 87.5b)
RoE = 14.76% (Net Income TTM 6.82b / Total Stockholder Equity 46.2b)
RoCE = 11.61% (EBIT 6.97b / Capital Employed (Equity 46.2b + L.T.Debt 13.9b))
RoIC = 8.92% (NOPAT 5.84b / Invested Capital 65.4b)
WACC = 5.89% (E(87.1b)/V(89.4b) * Re(5.31%) + D(2.32b)/V(89.4b) * Rd(32.97%) * (1-Tc(0.16)))
Discount Rate = 5.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.32 | Cagr: 0.12%
[DCF] Terminal Value 74.60% ; FCFF base≈6.90b ; Y1≈6.58b ; Y5≈6.30b
[DCF] Fair Price = 102.1 (EV 99.0b - Net Debt 876.0m = Equity 98.2b / Shares 961.7m; r=8.35% [WACC [floored]]; 5y FCF grow -5.94% → 2.50% )
EPS Correlation: 97.95 | EPS CAGR: 7.39% | SUE: 0.27 | # QB: 0
Revenue Correlation: 92.88 | Revenue CAGR: 2.73% | SUE: -1.96 | # QB: -1
EPS current Quarter (2026-09-30): EPS=1.69 | Chg30d=-1.75% | Revisions=-12% | Analysts=5
EPS current Year (2026-12-31): EPS=6.62 | Chg30d=+0.32% | Revisions=+0% | GrowthEPS=-3.0% | GrowthRev=-1.3%
EPS next Year (2027-12-31): EPS=6.85 | Chg30d=-0.50% | Revisions=-30% | GrowthEPS=+3.5% | GrowthRev=+2.9%
[Analyst] Revisions Ratio: -19% (up=7, down=11)